News MSD, Moderna skin cancer vaccine scores historic phase 3 win Strong phase 3 results for Moderna's individualised skin cancer vaccine could pave the way for a leap forward in the field.
News Third time lucky for Replimune as FDA OKs melanoma drug At its third attempt, Replimune has finally won FDA approval for its advanced melanoma treatment RP1, now named Tudriqev and its first product.
News Adcomm backs Replimune melanoma drug, despite data concern Replimune's RP1 immunotherapy for melanoma clears advisory committee vote by 10 to three, despite FDA concerns about the design of the IGNYTE study.
News Another LAG-3 setback as Regeneron drug fails phase 3 trial Regeneron's LAG-3 inhibitor fianlimab has missed the mark in a highly anticipated melanoma trial, hitting its share price.
News FDA hands another rejection to Replimune's melanoma therapy Replimune has had its advanced melanoma treatment RP1 turned down by the FDA for a second time, prompting job losses.
News Data builds behind Moderna's skin cancer vaccine Five-year results with Moderna/MSD's melanoma jab show a 49% reduction in disease progression or death, boding well for phase 3 data later this year.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.